Linklaters advises on USD 11.0 bn financing by Novartis of the acquisition of Avidity Biosciences
Linklaters advised a global underwriting syndicate on an USD 11 billion SEC-registered bond issuance by Novartis. The proceeds will be used for general corporate purposes and to repay a bridge loan that financed Novartis' USD 12 billion acquisition of Avidity Biosciences. The international Linklaters team was led by Marco Carbonare, Kevin Roy, and Danelle Le Cren.
Biotech CAMP4 taps veteran CFO as it pushes SYNGAP1 drug to trial
CAMP4 Therapeutics (Nasdaq: CAMP) has appointed Michael MacLean, a veteran biotech CFO with over 35 years of experience, to its Board of Directors. This strategic move coincides with the company advancing its CMP-002 program for SYNGAP1-related disorder towards a planned first-in-human Phase 1/2 clinical trial. MacLean's extensive background includes leadership roles at Avidity Biosciences, Akcea Therapeutics, PureTech Health, and Biogen, bringing valuable financial and operational expertise to CAMP4 during this critical growth phase.
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
Atrium Therapeutics, a spin-off from Avidity Biosciences following its acquisition by Novartis, is pioneering precision RNA therapeutics for rare, genetic cardiomyopathies. The company, launched with $270 million in funding and a Novartis-validated delivery platform, aims to develop treatments that target the underlying cause of these severe heart conditions. Atrium plans to file INDs for its lead assets in late 2026 and 2027, with the potential to expand its reach beyond rare diseases to broader cardiomyopathy patient populations.
[15-12G] Avidity Biosciences, Inc. SEC Filing
This article announces an SEC filing by Avidity Biosciences, Inc. (RNAM) of Form 15, which is a certification and notice of termination of registration under Section 12(g) or suspension of duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. The filing was signed by Jaime Huertas, Secretary, on March 9, 2026. The company is headquartered in San Diego, California, and has common stock with a par value of $0.0001 per share.
Novartis, Avidity Deal Spins Out New RNA Co.
Atrium Therapeutics, a new RNA company, launched in February with $270 million in funding as a spinoff following Novartis' $12 billion acquisition of Avidity Biosciences. Atrium will focus on developing RNA therapeutics for rare muscle diseases, particularly in the precision cardiology space, leveraging Avidity's antibody-oligonucleotide conjugate (AOC) platform. The company plans to submit Investigational New Drug applications for two lead candidates, ATR 1072 and ATR 1086, later this year and in 2027, respectively, and retained Avidity's former CEO, Sarah Boyce, as chair of its board.
RNAM SEC Filings - Avidity Biosciences, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Avidity Biosciences's (Ticker: RNAM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-generated summaries, sentiment and impact scores from Rhea-AI, and end-of-day stock performance data to offer insights into market reactions. The resource is designed for investors and regulatory compliance professionals to navigate critical disclosures and financial reporting.
Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis
This article reports that Avidity Biosciences (RNA) saw its stock price reach an all-time high due to rumors of a potential $12-billion merger with Novartis. This speculative news has significantly boosted investor confidence in RNA.
Avidity Biosciences Inc (RNAM) Fundamental Analysis
This article provides a fundamental analysis of Avidity Biosciences Inc (RNAM), highlighting its weak financial fundamentals. Key concerns include a negative PE ratio, profit margin, and ROE, alongside weak or negative revenue and EPS growth. Despite these weaknesses, the company shows strengths in its cash position, PEG ratio, and current ratio, and is noted as potentially undervalued based on its PE and PEG ratios.
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Hold" from Analysts
Avidity Biosciences, Inc. (NASDAQ:RNA) has received an average "Hold" rating from twenty-one analysts, with an average 12-month price target of $69.57. Recent insider selling of 58,407 shares worth $4.23 million was noted, alongside a Q3 earnings miss where EPS of ($1.59) and revenue of $0.86 million fell short of expectations. The company, focused on developing antibody-oligonucleotide conjugate therapies, shows deeply negative margins and return on equity.
Avidity Biosciences, Inc.(NasdaqGM: RNAM) dropped from S&P TMI Index
Avidity Biosciences, Inc. (NasdaqGM: RNAM) has been removed from the S&P TMI Index, as announced on March 2, 2026. This follows several other recent removals from various S&P and Russell indices, including the S&P Global BMI Index, S&P Biotechnology Select Industry Index, and multiple Russell Growth and Value benchmarks, all noted around March 1-2, 2026. Avidity Biosciences is a biopharmaceutical company focused on developing antibody oligonucleotide conjugates (AOCs) for RNA therapeutics.
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The presentations will cover new data for their del-zota treatment for DMD44, patient experiences with del-desiran for DM1, and other research on muscular dystrophies. Avidity will also host an industry forum lunch event focused on biomarker advancements in rare neuromuscular diseases.
Operating expenses (excl. COGS) of Avidity Biosciences, Inc. – NASDAQ:RNAM
This article focuses on the operating expenses (excluding COGS) of Avidity Biosciences, Inc., traded on NASDAQ under the symbol RNAM. It appears to be a financial data page from TradingView, providing an overview of the company's financials for investors and analysts. The content itself is minimalist, primarily serving as a header for more detailed financial information presumably available on the platform.
Avidity Biosciences, Inc. (RNAM) Leadership & Management Team Analysis
This article provides an in-depth analysis of Avidity Biosciences, Inc.'s leadership and management team, highlighting key figures like CEO Sarah Boyce, her compensation, and tenure. It also details the experience of the broader management team and board of directors, alongside recent company updates and changes in executive roles and stock transactions. Financial data related to CEO compensation relative to company earnings is presented.
Avidity Biosciences (RNA) CLO disposes stock, options in Novartis merger
Avidity Biosciences' Chief Legal Officer, John B. Moriarty, reported the disposition of company equity, including 92,054 shares of Common Stock and stock options for 50,000 and 160,000 shares, due to a merger with Novartis AG. The Common Stock and underlying restricted stock units, as well as the stock options, were exchanged for cash based on the merger consideration of $72.00 per share. This transaction resulted in Moriarty holding no shares for the affected positions after the merger.
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
Atrium Therapeutics, a new spinout from Avidity Biosciences, launched with $270 million to develop RNA medicines for rare heart conditions, four months after Novartis acquired Avidity for $12 billion. Led by Avidity's former Chief Program Officer Kathleen Gallagher and chaired by its ex-CEO Sarah Boyce, Atrium will focus on areas like PRKAG2 syndrome and PLN cardiomyopathy, which were not part of the Novartis acquisition. The company leverages Avidity's pioneering work in targeted RNA delivery, specifically its methods for sending RNA medicines into muscle tissue.
Avidity Biosciences Announced Transfer or Voluntary Withdrawal of Listing
Avidity Biosciences (RNAM) announced its intent to delist from Nasdaq following a consummated merger. Trading of the company's common stock will be suspended on March 2, 2026, and a Form 15 will be filed to terminate registration and suspend reporting obligations after the Form 25 for delisting becomes effective. This information is based on an SEC filing from February 27, 2026.
Avidity Biosciences (Nasdaq:RNAM) - Stock Analysis
Avidity Biosciences (Nasdaq:RNAM) is a biopharmaceutical company engaged in developing RNA therapeutics. The company is currently unprofitable but is forecast to grow revenue by 51.74% per year, trading considerably below Simply Wall St's fair value estimate. Recent updates include final results from a Phase 1/2 trial for Myotonic Dystrophy Type 1 and an agreement for Novartis to acquire the company for $10.6 billion.
S&P 500 Futures Decline in Premarket Trading; Avidity Biosciences, Duolingo Lag
The Dow Jones Industrial Average fell sharply on Friday, dropping 522 points, but still managed to secure its tenth consecutive monthly gain. The S&P 500 and Nasdaq Composite also declined, on both the day and the month. Factors contributing to the market downturn included concerns about private-credit following a bank selloff, Block's workforce reduction announcement, and anxieties surrounding AI's impact on employment.
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
Atrium Therapeutics, a new biotech spinout from Novartis' acquisition of Avidity Biosciences, has officially debuted with $270 million in cash. Led by Kathleen Gallagher, the company will focus on advancing two preclinical small interfering RNA candidates, ATR 1072 and ATR 1086, for rare genetic heart conditions, with planned Phase 1 trials in late 2026 and 2027 respectively. Atrium inherited Avidity's stock market presence and aims to develop precision medicines for cardiac diseases.
Avidity Biosciences, Inc. $RNA Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly increased its stake in Avidity Biosciences, purchasing over 300,000 additional shares to own 0.62% of the company, valued at approximately $39.2 million. This comes despite Avidity missing quarterly earnings estimates and experiencing notable insider share sales from its CEO and CFO. Analysts currently hold a consensus "Hold" rating on the stock with an average target price of $69.57.
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida, from March 8-11, 2026. The presentations will cover data from its EXPLORE44 program for Duchenne muscular dystrophy (DMD44), patient journeys and treatment experiences in myotonic dystrophy type 1 (DM1), and research in facioscapulohumeral muscular dystrophy (FSHD). Avidity will also host an industry forum lunch focusing on biomarker advancements in rare neuromuscular diseases.
Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform
Avidity Biosciences announced the expansion of its RNA therapeutic discovery pipeline, adding new research and development candidates in skeletal muscle and cardiology. The company is leveraging its proprietary AOC platform to target previously untreatable diseases and continues to advance three rare disease programs in Phase 1/2 clinical development for myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). Avidity also maintains collaborations with Eli Lilly and Company and MyoKardia to further explore its AOC platform's potential.
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Avidity Biosciences (Nasdaq: RNA) announced it will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The presentations will cover new data from their EXPLORE44 program for Duchenne muscular dystrophy (DMD44) and insights into myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). Additionally, Avidity will host an industry forum lunch focusing on biomarker advancements in rare neuromuscular diseases.
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida. The presentations will cover data from their EXPLORE44 program for Duchenne muscular dystrophy, patient journeys and treatment experiences in Myotonic Dystrophy Type 1, and research on Facioscapulohumeral Muscular Dystrophy. Additionally, Avidity will host an industry forum lunch focusing on biomarker advancements in rare neuromuscular diseases.
One-year Duchenne study ties treatment to near-normal creatine kinase levels
Avidity Biosciences (NASDAQ: RNA) is set to present one oral and six poster presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in March. Key presentations will include 1-year data from their Phase 1/2 EXPLORE44 del-zota study for Duchenne muscular dystrophy (DMD44), which shows near normalization of creatine kinase levels and functional improvements. The company's upcoming presence at the conference highlights its continued focus on advancing RNA therapeutics for neuromuscular diseases.
A Look At Avidity Biosciences (RNA) Valuation After Strong Multi Year Shareholder Returns
Avidity Biosciences (RNA) has shown strong shareholder returns over the past three years, despite reporting significant net losses and modest revenue, indicating it's still in a development phase. The company's Price-to-Book ratio suggests it's valued similarly to high-growth peers, but a Discounted Cash Flow model indicates a substantial undervaluation compared to its current price. Investors are advised to consider the company's risks and growth potential carefully given the mixed signals in its valuation.
Avidity Biosciences (RNA) Posts FY 2025 US$237 Million Loss Challenging Bullish Growth Narratives
Avidity Biosciences (RNA) reported a net loss of US$237.1 million for FY 2025, bringing its trailing 12-month net loss to US$684.6 million against total revenue of US$18.8 million. While analysts forecast 51.4% annual revenue growth, challenging the current loss-making trend, critics point to expanding losses and a P/B ratio higher than the industry average. Despite a significant DCF fair value indicating undervaluation, the company faces skepticism regarding its path to profitability and shareholder dilution.
Rhumbline Advisers Decreases Stake in Avidity Biosciences, Inc. $RNA
Rhumbline Advisers reduced its stake in Avidity Biosciences (NASDAQ:RNA) by 9.9% in Q3, selling 17,288 shares and ending the quarter with 158,071 shares valued at approximately $6.887 million. While Rhumbline decreased its holdings, other institutions like Norges Bank and Bank of America significantly increased their positions. Insiders, however, have been net sellers, disposing of 58,407 shares in the last three months, though they still own 3.83% of the company.
Avidity Biosciences, Inc. SEC 10-K Report
Avidity Biosciences, Inc. has released its Form 10-K report for the fiscal year ended December 31, 2025, detailing financial performance, business operations, and strategic initiatives. The report highlights the company's focus on developing Antibody Oligonucleotide Conjugates (AOCs) for rare diseases, significant R&D expenses, and a planned merger with Novartis AG. Challenges include merger uncertainty, ongoing operating losses, and risks associated with manufacturing and market conditions.
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences announced it will adjourn its Special Meeting of Stockholders on February 23, 2026, and reconvene it on February 26, 2026. This adjournment is to allow more time to fulfill conditions for the pro rata distribution of Atrium Therapeutics, Inc. common stock to Avidity stockholders, which is a prerequisite for its proposed merger with Novartis AG. The distribution is expected on February 26, 2026, and the merger closing on February 27, 2026, with Avidity's common stock temporarily trading as "RNAM" during the distribution.
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences announced its plan to adjourn its special stockholders meeting scheduled for February 23, 2026, and reconvene it on February 26, 2026. This adjournment is intended to allow more time to satisfy conditions for the pro rata distribution of Atrium Therapeutics shares, which is a precursor to Avidity's proposed merger with Novartis AG. The Distribution is now expected on February 26, 2026, with the merger closing on February 27, 2026, both subject to closing conditions including stockholder approval.
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring Growth Potential Amidst 434% Revenue Surge
Avidity Biosciences, Inc. (RNA) is a biopharmaceutical company demonstrating significant growth, with a 434% revenue surge and an $11.26 billion market capitalization. The company is advancing several RNA therapeutic programs through clinical trials for diseases like myotonic dystrophy type 1 and muscular dystrophies. Despite substantial investment in its pipeline leading to negative EPS and free cash flow, analyst sentiment indicates cautious optimism for its long-term potential in biotechnology.
Avidity Biosciences to adjourn Feb 23 special meeting; Distribution expected Feb 26, Merger close Feb 27
Avidity Biosciences will adjourn its special meeting scheduled for February 23rd, 2026, and reconvene on February 26th, 2026. This adjournment is to allow more time for the completion of the SpinCo distribution. The company expects the distribution to occur on February 26th, 2026, with the merger with Novartis closing the following day, February 27th, 2026, pending closing conditions.
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences announced its intention to adjourn and reconvene a special meeting of stockholders to allow more time to satisfy conditions for the pro rata distribution of Atrium Therapeutics stock. This distribution is a prerequisite for its proposed merger with Novartis AG. The distribution is now expected on February 26, 2026, and the merger closing on February 27, 2026.
Biotech delays key vote as Atrium stock distribution, Novartis merger approach
Avidity Biosciences (NASDAQ: RNA) has adjourned its special meeting from February 23, 2026, to February 26, 2026, to allow for additional time to fulfill conditions for the pro rata distribution of Atrium Therapeutics (SpinCo) shares. This distribution is a prerequisite for the closing of Avidity's previously announced merger with Novartis AG. The SpinCo distribution is now expected on February 26, 2026, with the Novartis merger closing anticipated on February 27, 2026.
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences announced its intention to adjourn its special meeting of stockholders initially scheduled for February 23, 2026, and reconvene it on February 26, 2026. This adjournment is to allow additional time to satisfy the conditions for the pro rata distribution of Atrium Therapeutics, Inc. common stock, which is a prerequisite for the proposed merger with Novartis AG. The Distribution is now expected on February 26, 2026, and the merger closing on February 27, 2026, subject to closing conditions and stockholder approval.
A new delivery method muscling its way into the RNA space
Avidity Biosciences is pioneering a new RNA delivery method using antibody oligonucleotide conjugates (AOCs) to target diseases outside the liver, specifically muscle-related conditions. Their lead candidate, AOC 1001 for myotonic dystrophy Type 1, has shown promising results in clinical trials, demonstrating successful delivery to muscle cells and functional improvements. Avidity is expanding its pipeline to include treatments for Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy, aiming to revolutionize RNA-based therapies for a broader range of genetic diseases.
Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc
Avoro Capital Advisors LLC has increased its stake in Avidity Biosciences Inc. by 11.39%, acquiring 870,792 additional shares at $72.13 per share. This move boosts Avoro's total holdings in Avidity Biosciences to 8,515,792 shares, representing 5.54% of its $10.17 billion equity portfolio. Despite Avidity Biosciences being considered significantly overvalued with profitability challenges, Avoro's investment signals confidence in the biotech company's long-term potential and innovative RNA therapeutics pipeline.
Fiera Capital Corp Has $52.39 Million Position in Avidity Biosciences, Inc. $RNA
Fiera Capital Corp significantly increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA) by 53.8% in Q3, now holding 1,202,384 shares valued at $52.39 million. Several other institutional investors also adjusted their positions in the biotechnology company. Avidity Biosciences is trading at $72.86 with a market cap of $11.27 billion, and analysts have a "Hold" consensus rating on the stock with an average price target of $69.57.
Avidity Biosciences, Inc. $RNA Shares Acquired by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. significantly increased its stake in Avidity Biosciences (NASDAQ:RNA) by 173.2% in the third quarter, while other institutions also boosted their holdings. Despite this institutional interest, analyst sentiment has softened, resulting in a consensus "Hold" rating and a target price of $69.57. Insider selling, including by CEO Sarah Boyce, has been noted as the stock trades near its 52-week high.
Aberdeen Group plc Buys 25,000 Shares of Avidity Biosciences, Inc. $RNA
Aberdeen Group plc increased its stake in Avidity Biosciences, Inc. by 8.9% in the third quarter, purchasing an additional 25,000 shares to bring its total holdings to 304,828 shares valued at $13.28 million. Despite this institutional buying, company insiders, including a director and the CFO, have been net sellers, offloading over 58,000 shares worth approximately $4.23 million in the last quarter. Avidity Biosciences, currently trading near its one-year high, has an average analyst rating of "Hold" with a consensus price target of $69.57.
Avidity Biosciences Reports Del-desiran Clinical Trial Results
Avidity Biosciences reported positive clinical trial results for Del-desiran, demonstrating significant efficacy in reducing DMPK mRNA in patients with myotonic dystrophy type 1 (DM1) and showing functional improvements with a good safety profile. The company is advancing to a global Phase 3 HARBOR study, aiming for Del-desiran to be the first approved drug for DM1. However, recent analyst downgrades occurred due to Novartis's agreement to acquire Avidity Biosciences for $72 per share.
Assetmark Inc. Buys 21,507 Shares of Avidity Biosciences, Inc. $RNA
Assetmark Inc. significantly increased its stake in Avidity Biosciences, purchasing an additional 21,507 shares in the third quarter, bringing its total holdings to 51,186 shares. This institutional buying comes amidst notable insider selling, with the CFO and CEO disposing of shares totaling over $1.3 million. Avidity Biosciences, a clinical-stage biotech developing AOC therapies, currently has a consensus "Hold" rating from analysts with an average price target of $69.57.
Avidity Biosciences (RNA) to Release Earnings on Thursday
Avidity Biosciences (NASDAQ:RNA) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th. Analysts anticipate an EPS of ($1.24) and revenue of $1.982 million. The stock recently traded near its 52-week high, and Wall Street maintains a "Hold" consensus rating with a target price of $69.57, despite recent insider share sales.
Avidity’s myotonic dystrophy drug shows promising results in trial By Investing.com
Avidity Biosciences announced promising final results from its Phase 1/2 MARINA trial for delpacibart etedesiran (del-desiran), a drug targeting myotonic dystrophy type 1 (DM1). The drug demonstrated a significant reduction in DMPK mRNA and showed improvements in functional measures with an acceptable safety profile. Currently, del-desiran is undergoing a Phase 3 study, with topline data expected in the second half of 2026.
Avidity’s myotonic dystrophy drug shows promising results in trial
Avidity Biosciences announced promising final results from its Phase 1/2 MARINA trial for delpacibart etedesiran (del-desiran), a drug targeting myotonic dystrophy type 1 (DM1). The study showed a significant reduction in DMPK mRNA and improvements across various functional measures, with an acceptable safety profile. Del-desiran is now in a global Phase 3 HARBOR study, with topline data expected in the second half of 2026.
Avidity Biosciences Acquired by Novartis for $72 per Share
Halper Sadeh LLC is investigating Avidity Biosciences (NASDAQ: RNA) following its acquisition by Novartis for $72 per share in cash, probing potential violations of federal securities laws and fiduciary duties to shareholders. Two analysts, TD Cowen and Chardan, downgraded RNA to Hold and Neutral, respectively, after the merger announcement, adjusting their price targets to reflect the acquisition price. Avidity Biosciences, a biopharmaceutical company focused on RNA therapeutics, aims to expand its pipeline in cardiology and immunology through collaboration with Novartis.
Avidity Biosciences reports data from DMD treatment trials
Avidity Biosciences announced new data from its Phase 1/2 FORTITUDE trial for the Duchenne muscular dystrophy (DMD) treatment, del-ACAMO. The data showed that del-ACAMO led to a mean 48% reduction in dystrophin with expression in 75% of participants, although it did not meet the primary endpoint of increased dystrophin protein expression. The company plans to continue discussions with regulators regarding the path forward for this therapy.
Allianz Asset Management GmbH Invests $632,000 in Avidity Biosciences, Inc. $RNA
Allianz Asset Management GmbH recently acquired a new stake of 14,500 shares, valued at $632,000, in Avidity Biosciences (NASDAQ:RNA) during Q3. This investment comes despite recent insider selling, including CEO Sarah Boyce, totaling over $4.23 million in the past three months. While analysts have a consensus "Hold" rating with an average price target of $69.57, the stock is currently trading near its recent highs.
Avidity Biosciences reports data from DMD treatment trials
Avidity Biosciences has announced new data from its FORTITUDE and EXPLORE clinical trials, which are evaluating the efficacy of del-brax for treating Duchenne Muscular Dystrophy (DMD). The updated information includes 28-week cardiac function data from the FORTITUDE trial and 24-week muscle biopsy data from the EXPLORE trial.
